Pharmacokinetics, Pharmacodynamics, & Drug Metabolism Community

Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease - The AAPS Journal SpringerLink remove preview Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease - The AAPS Journal In August 2021, the US Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease (LOPD). The effectiveness and safety were studied in patients with LOPD and patients with infantile-onset Pompe disease (IOPD). View this on SpringerLink >

To view the full article through your AAPS membership:

Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal 

Enter your AAPS credentials

Click "Member Access to Journals"

Click on the The AAPS Journal cover.

Copy and paste the url into the "Search" box, and click search

The full article should appear.

 

Follow The AAPS Journal via Twitter: https://twitter.com/theaapsjournal

and by Linkedin,  https://www.linkedin.com/showcase/theaapsjournal/

------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------